Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat

Circulation

Volumn 98, Issue 21, 1998, Pages 2323-2330

  Nguyen, Quang Trinh ^a   Cernacek, Peter ^b   Calderoni, Angelino ^c   Stewart, Duncan J ^d   Picard, Pierre ^d   Sirois, Pierre ^e   White, Michel ^a   Rouleau, Jean L ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Endothelin; Infarction; Remodeling hemodynamics

Indexed keywords

ANGIOTENSIN; DARUSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; MESSENGER RNA;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART DILATATION; HEART INFARCTION; HEART LEFT VENTRICLE; HEART VENTRICLE REMODELING; HEMODYNAMICS; IMMUNOCYTOCHEMISTRY; LUNG ARTERY PRESSURE; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; RAT;

EID: 0032564332     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.21.2323     Document Type: Article

References (20)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
2. Li K, Stewart DJ, Rouleau JL. Myocardial contractile actions of endothelin-1 in rat and rabbit papillary muscle: role of endocardial endothelium. Circ Res. 1991;69:301-312.
3. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. 1994;46:325-415.
4. Omland T, Lie RT, Aakvaag A, Aarkand T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation. 1994;89:1573-1579.
5. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85:504-509.
6. Sutch G, Hunziker P, Kim JH, Bryzinski B, Schlatter P, Bertel O, Kiowski W. The effect of prolonged endothelin-antagonist therapy with bosentan in severe chronic heart failure. Eur J Clin Invest. 1996;26(suppl I):A51. Abstract.
7. Fraccarollo D, Hu K, Galuppo P, Gaudron P, Ertl G. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction. Circulation. 1997;96:3963-3973.
8. Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, Compagnon P, Macé B, Comoy E, Letac B, Thuillez C. Role of endog-enous endothelin in chronic heart failure. Circulation. 1997;96:1976-1982.
9. Sakai S, Miyauchi T, Sakurai T, Yamaguchi I, Kobayshi M, Goto K, Sugishita Y. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist: increased expression of the endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats. J Am Coll Cardiol. 1996;28:1580-1588.
10. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 1996;283:353-355.
11. Sakai S, Miyauchi T, Sakurai T, Kasuya Y, Ihara M, Yamaguchi I, Katsutoshi G, Sugishita Y. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure: marked increased in endothelin-1 production in the failing heart. Circulation. 1996;93:1214-1222.
12. Kiowski W, Sütsch G, Hunziker P, Müller P, Kim J, Oechslin E, Schmitt R, Jones R, Bertel O. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 1995;346:732-736.
13. Sütsch G, Hunziker P, Kim JH, Bryzinski B, Schlatter P, Bertel O, Kiowski W. The effect of prolonged endathelin-antagonist therapy with bosentan in severe chronic heart failure. Eur J Clin Invest. 1996;26(suppl I):A51. Abstract.
14. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implication. Circulation. 1990;81:1161-1172.
15. Pfeffer JM, Finn PV, Pfeffer MA. Endothelin-A receptor antagonism in rats with myocardial infarction and failure. J Am Coll Cardiol. 1997;29(suppl A):399A. Abstract.
16. Riechers H, Albrecht H, Amberg W, Baumann E, Bernard H, Böhm H, Klinge D, Kling A, Müller S, Raschack M, Unger L, Walker N, Wernet W. Discovery and optimization of a novel class of orally active non-peptidic endothelin-A receptor antagonists. J Med Chem. 1996;39:2123-2128.
17. A-receptor antagonist inhibits neointima formation induced by endothelial injury. Pharm Pharmacol Lett. 1996;6:90-92.
18. Bélichard P, Savard P, Cardinal R, Nadeau R, Gosselin H, Paradis P, Rouleau JL. Marked different effects on ventricular remodeling result in a decrease in inducibility of ventricular arrhythmias. J Am Coll Cardiol. 1994;23:505-513.
19. Forbes RD, Cernacek P, Zheng S, Gomersall M, Guttman RD. Increased endothelin expression in a rat cardiac allograft model of chronic vascular rejection. Transplantation. 1996;61:791-797.
20. 1B-adrenergic receptor mRNA in vascular smooth muscle cells. J Biol Chem. 1994;269:1705-1710.